Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

T. Flaherty, Keith; Puzanov, Igor; B. Kim, Kevin; Ribas, Antoni; A. McArthur, Grant; A. Sosman, Jeffrey; J. O’Dwyer, Peter; J. Lee, Richard; F. Grippo, Joseph; B. Nolop, K.; B. Chapman, Paul

doi:10.1056/nejmoa1002011

Public

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Published in New England Journal of Medicine • Aug 25, 2010

Authors:

Keith T. Flaherty

Igor Puzanov

Kevin B. Kim

Abstract

BACKGROUND: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease. METHODS: We conducted a multicenter, phase 1, dose-escalation trial of PLX4...

Subject

Medicine

Melanoma

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!